S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:BASI

Bioanalytical Systems Stock Forecast, Price & News

$17.04
+1.63 (+10.58 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.84
Now: $17.04
$18.60
50-Day Range
$11.55
MA: $14.25
$17.15
52-Week Range
$3.05
Now: $17.04
$18.60
Volume157,425 shs
Average Volume116,353 shs
Market Capitalization$189.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Headlines

Bioanalytical Systems, Inc. to Host Earnings Call
February 9, 2021 |  finance.yahoo.com
Inotiv Broadens Pathology Service Offerings
January 19, 2021 |  finance.yahoo.com
BASi Releases Earnings for Fourth Quarter of Fiscal 2020
December 21, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BASI
CUSIPN/A
Phone765-463-4527
Employees397
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.47 million
Cash Flow$0.03 per share
Book Value$0.69 per share

Profitability

Net Income$-4,680,000.00

Miscellaneous

Market Cap$189.67 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.05 out of 5 stars

Medical Sector

970th out of 1,960 stocks

Commercial Physical Research Industry

17th out of 42 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$17.04
+1.63 (+10.58 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BASI News and Ratings via Email

Sign-up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions

Is Bioanalytical Systems a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioanalytical Systems in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bioanalytical Systems stock.
View analyst ratings for Bioanalytical Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Bioanalytical Systems?

Wall Street analysts have given Bioanalytical Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bioanalytical Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bioanalytical Systems?

Bioanalytical Systems saw a decline in short interest in the month of January. As of January 29th, there was short interest totaling 34,500 shares, a decline of 20.7% from the January 14th total of 43,500 shares. Based on an average daily trading volume, of 94,600 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.5% of the company's shares are short sold.
View Bioanalytical Systems' Short Interest
.

When is Bioanalytical Systems' next earnings date?

Bioanalytical Systems is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Bioanalytical Systems
.

How were Bioanalytical Systems' earnings last quarter?

Bioanalytical Systems, Inc. (NASDAQ:BASI) announced its earnings results on Monday, December, 21st. The company reported ($0.16) EPS for the quarter. The company earned $15.77 million during the quarter. Bioanalytical Systems had a negative trailing twelve-month return on equity of 42.74% and a negative net margin of 7.75%.
View Bioanalytical Systems' earnings history
.

How has Bioanalytical Systems' stock price been impacted by Coronavirus (COVID-19)?

Bioanalytical Systems' stock was trading at $4.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BASI shares have increased by 295.4% and is now trading at $17.04.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BASI?

1 brokerages have issued 1-year price targets for Bioanalytical Systems' stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Bioanalytical Systems' share price to reach $17.00 in the next twelve months. This suggests that the stock has a possible downside of 0.2%.
View analysts' price targets for Bioanalytical Systems
or view top-rated stocks among Wall Street analysts.

Who are Bioanalytical Systems' key executives?

Bioanalytical Systems' management team includes the following people:
  • Mr. Robert W. Leasure Jr., Pres, CEO & Director (Age 61, Pay $529.23k)
  • Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D., Chief Strategy Officer & Director (Age 56, Pay $289.82k)
  • Mr. Joseph Earl Flynn, Chief Commercial Officer (Age 56, Pay $310k)
  • Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 76)
  • Ms. Beth A. Taylor CPA, CFO, VP of Fin. & Sec. (Age 56)
  • Mr. Daniel Thomas Oakley, Chief Operations Officer (Age 63)
  • Mr. William D. Pitchford, Chief HR Officer (Age 66)
  • Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 51)
  • Dr. Michael A. Baim Ph.D., Sr. VP of Analytical Operations (Age 64)
  • Dr. J. Scott Daniels, Sr. VP of DMPK

What is Jacqueline Lemke's approval rating as Bioanalytical Systems' CEO?

6 employees have rated Bioanalytical Systems CEO Jacqueline Lemke on Glassdoor.com. Jacqueline Lemke has an approval rating of 20% among Bioanalytical Systems' employees. This puts Jacqueline Lemke in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Bioanalytical Systems' key competitors?

What other stocks do shareholders of Bioanalytical Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioanalytical Systems investors own include Riot Blockchain (RIOT), The Boeing (BA), NVIDIA (NVDA), Overstock.com (OSTK), Enphase Energy (ENPH), Pure Storage (PSTG), Mastercard (MA), Main Street Capital (MAIN), QUALCOMM (QCOM) and Toll Brothers (TOL).

What is Bioanalytical Systems' stock symbol?

Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."

Who are Bioanalytical Systems' major shareholders?

Bioanalytical Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.43%), Next Century Growth Investors LLC (0.39%) and Virtu Financial LLC (0.09%). Company insiders that own Bioanalytical Systems stock include Beth Taylor, Daniel Thomas Oakley, Gregory Cole Davis, Jill Blumhoff, John E Sagartz, Philip A Downing, R Matthew Neff, Richard Allen Johnson, Robert Jr Leasure, Wendy Perrow and William D Pitchford.
View institutional ownership trends for Bioanalytical Systems
.

Which major investors are buying Bioanalytical Systems stock?

BASI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Next Century Growth Investors LLC, and Virtu Financial LLC. Company insiders that have bought Bioanalytical Systems stock in the last two years include Beth Taylor, Daniel Thomas Oakley, Gregory Cole Davis, Jill Blumhoff, John E Sagartz, Philip A Downing, R Matthew Neff, Richard Allen Johnson, Robert Jr Leasure, Wendy Perrow, and William D Pitchford.
View insider buying and selling activity for Bioanalytical Systems
or or view top insider-buying stocks.

How do I buy shares of Bioanalytical Systems?

Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioanalytical Systems' stock price today?

One share of BASI stock can currently be purchased for approximately $17.04.

How much money does Bioanalytical Systems make?

Bioanalytical Systems has a market capitalization of $189.67 million and generates $60.47 million in revenue each year. The company earns $-4,680,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Bioanalytical Systems have?

Bioanalytical Systems employs 397 workers across the globe.

What is Bioanalytical Systems' official website?

The official website for Bioanalytical Systems is www.basinc.com.

Where are Bioanalytical Systems' headquarters?

Bioanalytical Systems is headquartered at 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906.

How can I contact Bioanalytical Systems?

Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.